Nat Med. 1996 Jul;2(7):760-6.

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.

Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW, Kempf DJ.

Source

Department of Anti-Infective Research, Abbott Laboratories, Abbott Park, Illinois 60064, USA.

Abstract

Analysis of the HIV protease gene from the plasma of HIV-infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitor ritonavir. Mutants at valine-82, although insufficient to confer resistance, appeared first in most patients. Significant phenotypic resistance required multiple mutations in HIV protease, which emerged subsequently in an ordered, stepwise fashion. The appearance of resistance mutations was delayed in patients with higher plasma levels of ritonavir. Early mutants retained susceptibility to structurally diverse protease inhibitors, suggesting that dual protease inhibitor therapy might increase the duration of viral suppression.

PMID:: 8673921; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Supplemental Content

Save items

Related citations in PubMed

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. [Antivir Ther. 2002]
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R, Sun E. Antivir Ther. 2002 Sep; 7(3):165-74.
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). [AIDS. 1996]
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).
Schmit JC, Ruiz L, Clotet B, Raventos A, Tor J, Leonard J, Desmyter J, De Clercq E, Vandamme AM. AIDS. 1996 Aug; 10(9):995-9.
Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. [J Virol. 2005]
Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H, King MS, King K, Molla A, Brun S, Kempf DJ. J Virol. 2005 Mar; 79(6):3329-38.
Review The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. [Antivir Ther. 2004]
Review The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D, Schapiro JM, Brenner BG, Wainberg MA. Antivir Ther. 2004 Jun; 9(3):301-14.
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection. [Drugs. 2003]
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS, Goa KL. Drugs. 2003; 63(8):769-802.

See reviews... See all...

Cited by over 100 PubMed Central articles

HIV-1 Antiretroviral Drug Therapy. [Cold Spring Harb Perspect Med....]
HIV-1 Antiretroviral Drug Therapy.
Arts EJ, Hazuda DJ. Cold Spring Harb Perspect Med. 2012 Apr; 2(4):a007161.
Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity. [Retrovirology. 2012]
Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.
van Maarseveen NM, Andersson D, Lepšík M, Fun A, Schipper PJ, de Jong D, Boucher CA, Nijhuis M. Retrovirology. 2012 Apr 1; 9:29. Epub 2012 Apr 1.
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. [HIV Seq Compend. 2001]
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.
Shafer RW, Dupnik K, Winters MA, Eshleman SH. HIV Seq Compend. 2001; 2001:1-51.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound
PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Ordered accumulation of mutations in HIV protease confers resistance to ritonavi...
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.
Nat Med. 1996 Jul ;2(7):760-6.

PubMed
Treatment practices for degedege, a locally recognized febrile illness, and impl...
Treatment practices for degedege, a locally recognized febrile illness, and implications for strategies to decrease mortality from severe malaria in Bagamoyo District, Tanzania.
Trop Med Int Health. 1996 Jun ;1(3):305-13.

PubMed
Communicating information to patients: the use of cartoon illustrations to impro...
Communicating information to patients: the use of cartoon illustrations to improve comprehension of instructions.
Acad Emerg Med. 1996 Mar ;3(3):264-70.

PubMed
The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis.
The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis.
Nat Struct Biol. 1996 Jul ;3(7):619-25.

PubMed
Transcriptional effects of superinfection in HIV chronically infected T cells: s...
Transcriptional effects of superinfection in HIV chronically infected T cells: studies in dually infected clones.
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 1 ;12(4):329-42.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.

Source

Abstract

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by over 100 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information